Gemcitabine in hematologic malignancies.
Gemcitabine in hematologic malignancies.
复制标题
吉西他滨治疗血液恶性肿瘤。
DOI：
10.1097/00001622-200111000-00015
复制
发表时间：
2001
影响因子：
3.4
通讯作者：
Rosen,S
中科院分区：
文献类型：
--
作者：
Nabhan,C;Krett,N;Gandhi,V;Rosen,S
吉西他滨是一种嘧啶类似物，在实体肿瘤中显示出显著的活性。吉西他滨通过链终止和核糖核苷酸还原酶抑制来抑制DNA合成。在最初的第一阶段和第二阶段研究中，吉西他滨的毒性很低，作为单一药物和联合治疗的耐受性很好。近年来，吉西他滨在血液系统恶性肿瘤中的作用受到越来越多的关注。吉西他滨在难治性霍奇金病患者、非霍奇金淋巴瘤、皮肤T细胞淋巴瘤和急性白血病患者中表现出良好的活性。在骨髓瘤和白血病细胞系中，有大量证据表明吉西他滨在体外具有活性。吉西他滨在这些疾病中的活性将为将该药纳入早期治疗阶段铺平道路。
Gemcitabine is a pyrimidine analogue that showed significant activity in solid malignancies. Gemcitabine acts by inhibiting DNA synthesis through chain termination and ribonucleotide reductase inhibition. During initial phase I and II studies, gemcitabine had a low toxicity profile and was well tolerated as a single agent and in combination therapy. Recently, there has been more interest in studying the activity of gemcitabine in hematologic malignancies. Gemcitabine demonstrated good activity in refractory Hodgkin disease patients, non-Hodgkin lymphoma, cutaneous T-cell lymphoma, and acute leukemias. There is a preponderance of evidence on the activity of gemcitabine in vitro in myeloma and leukemic cell lines. The activity of gemcitabine in these disorders will pave the way for incorporating this agent into the early phases of therapy.